A	O
novel	O
mutation	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
FY*B	B-DNA
allele	I-DNA
of	O
the	O
Duffy	B-DNA
chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
is	O
associated	O
with	O
an	O
altered	O
erythrocyte	O
phenotype	O
.	O

The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O

Antibodies	B-protein
to	O
Duffy	B-protein
antigens	I-protein
are	O
responsible	O
for	O
some	O
cases	O
of	O
transfusion	O
incompatibility	O
and	O
newborn	O
hemolytic	O
disease	O
.	O

The	O
Duffy	B-protein
protein	I-protein
is	O
a	O
receptor	O
for	O
the	O
Plasmodium	B-protein
vivax	I-protein
erythrocyte-binding	I-protein
protein	I-protein
and	O
is	O
also	O
a	O
receptor	O
for	O
various	O
chemokines	B-protein
(	O
thus	O
renamed	O
Duffy	B-protein
Antigen	I-protein
Receptor	I-protein
for	I-protein
Chemokines	I-protein
[	O
DARC	B-protein
]	O
)	O
.	O

The	O
two	O
Duffy	B-protein
polymorphic	I-protein
antigens	I-protein
,	O
Fya	B-protein
and	O
Fyb	B-protein
(	O
coded	O
by	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
)	O
,	O
are	O
present	O
on	O
erythrocyte	B-protein
membranes	I-protein
.	O

The	O
Fy	O
(	O
a-b-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non-Ashkenazi	O
Jewish	O
groups	O
.	O

The	O
Fy	O
(	O
a-b-	O
)	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
FY*B	B-DNA
promoter	I-DNA
at	O
the	O
GATA	B-DNA
box	I-DNA
that	O
abolishes	O
the	O
expression	O
of	O
erythrocyte	B-protein
Duffy	I-protein
protein	I-protein
.	O

We	O
describe	O
here	O
a	O
novel	O
mutation	O
,	O
present	O
in	O
the	O
FY*B	B-DNA
coding	I-DNA
sequence	I-DNA
(	O
271C	O
--	O
>	O
T	O
)	O
,	O
that	O
is	O
associated	O
with	O
some	O
Fy	O
(	O
b-	O
)	O
phenotypes	O
among	O
non-Ashkenazi	O
Jews	O
and	O
among	O
Brazilian	O
blacks	O
.	O

The	O
mutation	O
is	O
present	O
in	O
Fy	O
(	O
b-	O
)	O
individuals	O
,	O
who	O
have	O
wild-type	B-DNA
FY*B	I-DNA
GATA	I-DNA
and	O
carry	O
the	O
previously	O
described	O
304G	O
--	O
>	O
A	O
substitution	O
.	O

The	O
271C	O
--	O
>	O
T	O
and	O
304G	O
--	O
>	O
A	O
can	O
be	O
identified	O
by	O
restriction	B-DNA
enzyme-generated	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
.	O

The	O
271C	O
--	O
>	O
T	O
substitution	O
represents	O
a	O
considerable	O
change	O
in	O
chemical	O
nature	O
(	O
Arg91	O
--	O
>	O
Cys	O
)	O
,	O
one	O
which	O
may	O
affect	O
the	O
antigenic	O
determinants	O
of	O
DARC	B-protein
,	O
and	O
thus	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
mutation	O
may	O
have	O
implications	O
for	O
some	O
physiological	O
roles	O
of	O
DARC	B-protein
and	O
be	O
of	O
interest	O
in	O
malaria	O
research	O
and	O
in	O
studies	O
of	O
population	O
genetics	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

RAPID	NULL
COMMUNICATION	NULL
A	NULL
Novel	NULL
Mutation	NULL
in	NULL
the	NULL
Coding	NULL
Sequence	NULL
of	NULL
the	NULL
FY*B	NULL
Allele	NULL
of	NULL
the	NULL
Duffy	NULL
Chemokine	NULL
Receptor	NULL
Gene	NULL
Is	NULL
Associated	NULL
With	NULL
an	NULL
Altered	NULL
Erythrocyte	NULL
Phenotype	NULL
By	NULL
Niva	NULL
Parasol	NULL
,	NULL
Marion	NULL
Reid	NULL
,	NULL
Maria	NULL
Rios	NULL
,	NULL
Lilian	NULL
Castilho	NULL
,	NULL
lana	NULL
Harari	NULL
,	NULL
and	NULL
Nechama	NULL
S.	NULL
Kosower	NULL
The	NULL
Duffy	NULL
blood	NULL
group	NULL
system	NULL
is	NULL
of	NULL
clinical	NULL
and	NULL
biological	NULL
significance	NULL
.	NULL

Antibodies	NULL
to	NULL
Duffy	NULL
antigens	NULL
are	NULL
responsible	NULL
for	NULL
some	NULL
cases	NULL
of	NULL
transfusion	NULL
incompatibility	NULL
and	NULL
newborn	NULL
hemolytic	NULL
disease	NULL
.	NULL

The	NULL
Duffy	NULL
protein	NULL
is	NULL
a	NULL
receptor	NULL
for	NULL
the	NULL
Plasmodium	NULL
vivax	NULL
erythrocyte-binding	NULL
protein	NULL
and	NULL
is	NULL
also	NULL
a	NULL
receptor	NULL
for	NULL
various	NULL
chemokines	NULL
(	NULL
thus	NULL
renamed	NULL
Duffy	NULL
Antigen	NULL
Receptor	NULL
for	NULL
Chemokines	NULL
[	NULL
DARC	NULL
]	NULL
)	NULL
.	NULL

The	NULL
two	NULL
Duffy	NULL
polymorphic	NULL
antigens	NULL
,	NULL
Fy*®	NULL
and	NULL
Fy	NULL
``	NULL
(	NULL
coded	NULL
by	NULL
the	NULL
FY*	NULL
A	NULL
and	NULL
FY*B	NULL
alleles	NULL
)	NULL
,	NULL
are	NULL
present	NULL
on	NULL
erythrocyte	NULL
membranes	NULL
.	NULL

The	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotype	NULL
is	NULL
the	NULL
predominant	NULL
one	NULL
in	NULL
populations	NULL
of	NULL
black	NULL
people	NULL
and	NULL
also	NULL
occurs	NULL
in	NULL
other	NULL
populations	NULL
,	NULL
including	NULL
some	NULL
non-Ashkenazi	NULL
Jewish	NULL
groups	NULL
.	NULL

The	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotype	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
FY*B	NULL
promoter	NULL
at	NULL
the	NULL
GATA	NULL
box	NULL
that	NULL
abolishes	NULL
the	NULL
expression	NULL
of	NULL
erythrocyte	NULL
Duffy	NULL
protein	NULL
.	NULL

We	NULL
describe	NULL
here	NULL
a	NULL
novel	NULL
muta-	NULL
HE	NULL
DUFFY	NULL
BLOOD	NULL
GROUP	NULL
system	NULL
is	NULL
significant	NULL
in	NULL
humans	NULL
,	NULL
and	NULL
novel	NULL
mutations	NULL
with	NULL
functional	NULL
conse-quences	NULL
,	NULL
such	NULL
as	NULL
the	NULL
one	NULL
we	NULL
report	NULL
here	NULL
,	NULL
are	NULL
of	NULL
considerable	NULL
interest	NULL
.	NULL

The	NULL
two	NULL
Duffy	NULL
polymorphic	NULL
antigens	NULL
,	NULL
Fy®	NULL
and	NULL
Fy®	NULL
,	NULL
are	NULL
carried	NULL
on	NULL
proteins	NULL
produced	NULL
by	NULL
the	NULL
Duffy	NULL
gene	NULL
alleles	NULL
FY*A	NULL
and	NULL
FY*B	NULL
.	NULL

The	NULL
antisera	NULL
,	NULL
anti-Fy*	NULL
and	NULL
anti-Fy®	NULL
,	NULL
define	NULL
four	NULL
major	NULL
erythrocyte	NULL
Duffy	NULL
phenotypes	NULL
:	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
,	NULL
Fy	NULL
(	NULL
a-b+	NULL
)	NULL
,	NULL
b+	NULL
)	NULL
,	NULL
and	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
.	NULL
'	NULL

>	NULL
The	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotype	NULL
is	NULL
rare	NULL
among	NULL
white	NULL
and	NULL
Asian	NULL
populations	NULL
,	NULL
whereas	NULL
it	NULL
is	NULL
the	NULL
predominant	NULL
phenotype	NULL
among	NULL
populations	NULL
of	NULL
black	NULL
people	NULL
,	NULL
especially	NULL
those	NULL
originating	NULL
in	NULL
West	NULL
Africa	NULL
.	NULL
``	NULL

The	NULL
gene	NULL
,	NULL
the	NULL
first	NULL
one	NULL
to	NULL
be	NULL
assigned	NULL
to	NULL
a	NULL
specific	NULL
autosome	NULL
,	NULL
``	NULL
has	NULL
been	NULL
mapped	NULL
to	NULL
1422-23	NULL
.	NULL
``	NULL

The	NULL
gene	NULL
has	NULL
been	NULL
cloned	NULL
and	NULL
sequenced®	NULL
and	NULL
shown	NULL
to	NULL
have	NULL
two	NULL
exons	NULL
.	NULL
``	NULL

The	NULL
FY*A	NULL
and	NULL
FY*B	NULL
alleles	NULL
differ	NULL
by	NULL
a	NULL
single-base	NULL
substitution	NULL
at	NULL
nucleotide	NULL
131	NULL
of	NULL
the	NULL
cDNA	NULL
(	NULL
A	NULL
in	NULL
FY*B	NULL
and	NULL
G	NULL
in	NULL
FY*A	NULL
)	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
polymorphism	NULL
at	NULL
amino	NULL
acid	NULL
residue	NULL
44	NULL
,	NULL
with	NULL
aspartic	NULL
acid	NULL
(	NULL
Asp	NULL
)	NULL
in	NULL
Fy®	NULL
and	NULL
glycine	NULL
(	NULL
Gly	NULL
)	NULL
in	NULL
Fy	NULL
#	NULL
®.°	NULL
(	NULL
The	NULL
numbering	NULL
of	NULL
nucleotides	NULL
and	NULL
amino	NULL
acid	NULL
residues	NULL
used	NULL
here	NULL
is	NULL
according	NULL
to	NULL
the	NULL
cDNA	NULL
and	NULL
predicted	NULL
protein	NULL
sequence	NULL
based	NULL
on	NULL
a	NULL
single	NULL
exon	NULL
published	NULL
by	NULL
Chaudhuri	NULL
et	NULL
al	NULL
.	NULL

The	NULL
amino	NULL
acid	NULL
44	NULL
cited	NULL
here	NULL
would	NULL
be	NULL
amino	NULL
acid	NULL
42	NULL
,	NULL
as	NULL
predicted	NULL
by	NULL
Iwamoto	NULL
et	NULL
al	NULL
,	NULL
``	NULL
based	NULL
on	NULL
a	NULL
spliced	NULL
transcript	NULL
of	NULL
two	NULL
exons	NULL
.	NULL
)	NULL

The	NULL
presence	NULL
of	NULL
guanine	NULL
at	NULL
this	NULL
site	NULL
generates	NULL
a	NULL
Ban	NULL
I	NULL
restriction	NULL
site	NULL
in	NULL
FY*A	NULL
,	NULL
thus	NULL
allowing	NULL
the	NULL
identification	NULL
of	NULL
FY*A	NULL
and	NULL
FY*B	NULL
by	NULL
Ban	NULL
I	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
(	NULL
RFLP	NULL
)	NULL
.	NULL

*	NULL
!	NULL

°	NULL
A	NULL
substitution	NULL
of	NULL
T	NULL
to	NULL
C	NULL
at	NULL
the	NULL
GATA	NULL
box	NULL
of	NULL
the	NULL
FY*B	NULL
promoter	NULL
(	NULL
-46T	NULL
-	NULL
C	NULL
)	NULL
(	NULL
based	NULL
on	NULL
numbering	NULL
by	NULL
Tournamille	NULL
et	NULL
al	NULL
``	NULL
)	NULL
has	NULL
been	NULL
found	NULL
in	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
black	NULL
individuals	NULL
.	NULL
``	NULL

This	NULL
mutation	NULL
disrupts	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
GATA-1	NULL
erythroid	NULL
transcription	NULL
factor	NULL
,	NULL
results	NULL
in	NULL
a	NULL
silent	NULL
FY*B	NULL
allele	NULL
in	NULL
erythroid	NULL
cells	NULL
,	NULL
and	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
most	NULL
cases	NULL
of	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
erythrocytes	NULL
in	NULL
the	NULL
black	NULL
populations	NULL
.	NULL

``	NULL
!	NULL

The	NULL
GATA	NULL
mutation	NULL
generates	NULL
a	NULL
Sty	NULL
I	NULL
restriction	NULL
site	NULL
,	NULL
allowing	NULL
the	NULL
identification	NULL
of	NULL
this	NULL
mutation	NULL
by	NULL
RFLP	NULL
.	NULL
``	NULL

The	NULL
Duffy	NULL
gene	NULL
product	NULL
is	NULL
a	NULL
transmembrane	NULL
glycoprotein	NULL
of	NULL
35	NULL
to	NULL
43	NULL
kD	NULL
.	NULL

The	NULL
Duffy	NULL
antigens	NULL
are	NULL
important	NULL
in	NULL
transfusion	NULL
incompatibility	NULL
and	NULL
hemolytic	NULL
disease	NULL
of	NULL
the	NULL
newborn	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
Duffy	NULL
protein	NULL
is	NULL
a	NULL
receptor	NULL
for	NULL
the	NULL
erythrocyte-binding	NULL
protein	NULL
of	NULL
Plasmodium	NULL
vivax	NULL
;	NULL
the	NULL
resistance	NULL
in	NULL
West	NULL
Blood	NULL
,	NULL
Vol	NULL
92	NULL
,	NULL
No	NULL
7	NULL
(	NULL
October	NULL
1	NULL
)	NULL
,	NULL
1998	NULL
:	NULL
pp	NULL
2237-2243	NULL
tion	NULL
,	NULL
present	NULL
in	NULL
the	NULL
FY*	NULL
B	NULL
coding	NULL
sequence	NULL
(	NULL
2710	NULL
-	NULL
T	NULL
)	NULL
,	NULL
that	NULL
is	NULL
associated	NULL
with	NULL
some	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotypes	NULL
among	NULL
non-Ashkenazi	NULL
Jew	NULL
s	NULL
and	NULL
among	NULL
Brazilian	NULL
blacks	NULL
.	NULL

The	NULL
mutation	NULL
is	NULL
present	NULL
in	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
individuals	NULL
,	NULL
who	NULL
have	NULL
wild-type	NULL
FY*B	NULL
GATA	NULL
and	NULL
carry	NULL
the	NULL
previously	NULL
described	NULL
304G	NULL
-	NULL
A	NULL
substitu-tion	NULL
.	NULL

The	NULL
271C	NULL
-	NULL
T	NULL
and	NULL
304G	NULL
-	NULL
A	NULL
can	NULL
be	NULL
identified	NULL
by	NULL
restriction	NULL
enzyme-generated	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphisms	NULL
.	NULL

The	NULL
271C	NULL
-	NULL
T	NULL
substitution	NULL
represents	NULL
a	NULL
considerable	NULL
change	NULL
in	NULL
chemical	NULL
nature	NULL
(	NULL
Arg91	NULL
-	NULL
Cys	NULL
)	NULL
,	NULL
one	NULL
which	NULL
may	NULL
affect	NULL
the	NULL
antigenic	NULL
determinants	NULL
of	NULL
DARC	NULL
,	NULL
and	NULL
thus	NULL
be	NULL
of	NULL
clinical	NULL
significance	NULL
.	NULL

The	NULL
mutation	NULL
may	NULL
have	NULL
implications	NULL
for	NULL
some	NULL
physiological	NULL
roles	NULL
of	NULL
DARC	NULL
and	NULL
be	NULL
of	NULL
interest	NULL
in	NULL
malaria	NULL
research	NULL
and	NULL
in	NULL
studies	NULL
of	NULL
population	NULL
genetics	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

African	NULL
populations	NULL
to	NULL
infection	NULL
by	NULL
P	NULL
vivax	NULL
malarial	NULL
parasites	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
the	NULL
high	NULL
incidence	NULL
of	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
in	NULL
these	NULL
populations	NULL
.	NULL
``	NULL

The	NULL
Duffy	NULL
protein	NULL
has	NULL
also	NULL
been	NULL
identified	NULL
as	NULL
a	NULL
receptor	NULL
for	NULL
various	NULL
chemokines	NULL
and	NULL
renamed	NULL
as	NULL
Duffy	NULL
Antigen	NULL
Receptor	NULL
for	NULL
Chemokines	NULL
(	NULL
DARC	NULL
)	NULL
.	NULL

DARC	NULL
is	NULL
expressed	NULL
in	NULL
various	NULL
tissues	NULL
,	NULL
where	NULL
it	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
endothelial	NULL
cells	NULL
lining	NULL
postcapillary	NULL
venules	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
identified	NULL
in	NULL
cerebellar	NULL
Purkinje	NULL
cells	NULL
.	NULL

DARC	NULL
may	NULL
have	NULL
important	NULL
physiological	NULL
functions	NULL
in	NULL
homeostatic	NULL
processes	NULL
in	NULL
some	NULL
brain	NULL
regions	NULL
and	NULL
in	NULL
processes	NULL
involving	NULL
inflammatory	NULL
chemokines	NULL
.	NULL

!	NULL

924	NULL
Several	NULL
examples	NULL
of	NULL
erythrocytes	NULL
have	NULL
been	NULL
described	NULL
that	NULL
exhibit	NULL
weak	NULL
reactivity	NULL
with	NULL
some	NULL
anti-Fy®	NULL
sera	NULL
,	NULL
and	NULL
no	NULL
reactivity	NULL
with	NULL
others	NULL
,	NULL
thereby	NULL
giving	NULL
apparent	NULL
discrepancies	NULL
between	NULL
the	NULL
Fy®	NULL
phenotype	NULL
and	NULL
genotype	NULL
.	NULL

>	NULL
>	NULL
>	NULL
``	NULL
``	NULL
In	NULL
the	NULL
course	NULL
of	NULL
work	NULL
on	NULL
possible	NULL
association	NULL
of	NULL
schizophrenia	NULL
with	NULL
Duffy	NULL
antigens	NULL
,	NULL
'	NULL
``	NULL
``	NULL
``	NULL
we	NULL
found	NULL
a	NULL
sample	NULL
for	NULL
which	NULL
the	NULL
erythrocyte	NULL
phenotype	NULL
of	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
(	NULL
as	NULL
determined	NULL
by	NULL
standard	NULL
agglutination	NULL
assays	NULL
)	NULL
did	NULL
not	NULL
correspond	NULL
to	NULL
the	NULL
Duffy	NULL
genotype	NULL
.	NULL

This	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Human	NULL
Genetics	NULL
,	NULL
Sackler	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Tel-Aviv	NULL
University	NULL
,	NULL
Tel	NULL
Aviv	NULL
,	NULL
Israel	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Molecular	NULL
Genotyping	NULL
,	NULL
New	NULL
York	NULL
Blood	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
;	NULL
and	NULL
the	NULL
Blood	NULL
Services	NULL
Center	NULL
,	NULL
Magen	NULL
David	NULL
Adom	NULL
,	NULL
Tel-Hashomer	NULL
,	NULL
Israel	NULL
.	NULL

Submitted	NULL
May	NULL
11	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
July	NULL
9	NULL
,	NULL
1998	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Israel	NULL
Mental	NULL
Health	NULL
Association	NULL
(	NULL
Enosh	NULL
)	NULL
,	NULL
by	NULL
the	NULL
Pioneer	NULL
Fund	NULL
,	NULL
and	NULL
by	NULL
the	NULL
Igo	NULL
Ornstein	NULL
Chair	NULL
for	NULL
the	NULL
Study	NULL
of	NULL
Geriatrics	NULL
(	NULL
to	NULL
N.S.K	NULL
.	NULL
)	NULL

;	NULL
by	NULL
a	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Specialized	NULL
Center	NULL
of	NULL
Research	NULL
(	NULL
SCOR	NULL
)	NULL
grant	NULL
in	NULL
Transfusion	NULL
Medicine	NULL
and	NULL
Biology	NULL
No	NULL
.	NULL

HL54459	NULL
(	NULL
to	NULL
M.R	NULL
.	NULL
)	NULL

;	NULL
and	NULL
by	NULL
Fundagao	NULL
de	NULL
Amparo	NULL
&	NULL
Pesquisa	NULL
do	NULL
Estado	NULL
de	NULL
So	NULL
Paulo	NULL
,	NULL
Brazil	NULL
(	NULL
to	NULL
L.C	NULL
.	NULL
)	NULL

.	NULL

This	NULL
work	NULL
is	NULL
in	NULL
partial	NULL
fulfillment	NULL
of	NULL
the	NULL
requirements	NULL
for	NULL
the	NULL
PhD	NULL
degree	NULL
from	NULL
Tel	NULL
Aviv	NULL
University	NULL
(	NULL
N.P	NULL
.	NULL
)	NULL

.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Nechama	NULL
S.	NULL
Kosower	NULL
,	NULL
MD	NULL
,	NULL
Department	NULL
of	NULL
Human	NULL
Genetics	NULL
,	NULL
Sackler	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Tel-Aviv	NULL
University	NULL
,	NULL
Tel	NULL
Aviv	NULL
69978	NULL
,	NULL
Israel	NULL
;	NULL
e-mail	NULL
:	NULL
nkosower	NULL
@	NULL
ccsg.tau.ac.il	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/98/9207-0057	NULL
$	NULL
3.00/0	NULL
2237	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2238	NULL
sample	NULL
was	NULL
found	NULL
to	NULL
be	NULL
FY*B/FY*B	NULL
as	NULL
determined	NULL
by	NULL
Ban	NULL
I	NULL
RFLP	NULL
,	NULL
and	NULL
only	NULL
heterozygous	NULL
for	NULL
the	NULL
mutation	NULL
at	NULL
the	NULL
GATA	NULL
box	NULL
,	NULL
as	NULL
identified	NULL
by	NULL
Sty	NULL
I	NULL
RFLP	NULL
.	NULL
``	NULL

DNA	NULL
sequencing	NULL
showed	NULL
two	NULL
mutations	NULL
in	NULL
the	NULL
coding	NULL
sequence	NULL
,	NULL
a	NULL
novel	NULL
mutation	NULL
at	NULL
nucleotide	NULL
(	NULL
nt	NULL
)	NULL
271	NULL
from	NULL
C	NULL
to	NULL
T	NULL
(	NULL
271C	NULL
-	NULL
T	NULL
)	NULL
,	NULL
and	NULL
the	NULL
previously	NULL
reported	NULL
mutation	NULL
at	NULL
nt	NULL
304	NULL
from	NULL
G	NULL
to	NULL
A	NULL
(	NULL
304	NULL
G	NULL
-	NULL
A	NULL
)	NULL
.8	NULL
Subsequently	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
-RFLP	NULL
assays	NULL
were	NULL
established	NULL
to	NULL
screen	NULL
for	NULL
these	NULL
mutations	NULL
.	NULL

As	NULL
described	NULL
here	NULL
,	NULL
the	NULL
simultaneous	NULL
presence	NULL
of	NULL
these	NULL
two	NULL
mutations	NULL
resulted	NULL
in	NULL
the	NULL
silencing	NULL
of	NULL
the	NULL
Fy	NULL
``	NULL
antigen	NULL
in	NULL
erythrocytes	NULL
.	NULL

This	NULL
phenomenon	NULL
is	NULL
of	NULL
clinical	NULL
significance	NULL
and	NULL
may	NULL
have	NULL
implications	NULL
for	NULL
physiological	NULL
roles	NULL
of	NULL
DARC	NULL
in	NULL
tissues	NULL
other	NULL
than	NULL
erythrocytes	NULL
,	NULL
and	NULL
it	NULL
may	NULL
be	NULL
of	NULL
interest	NULL
in	NULL
studies	NULL
of	NULL
population	NULL
genetics	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Phenotyping	NULL
of	NULL
erythrocyte	NULL
Duffy	NULL
antigens	NULL
.	NULL

Blood	NULL
samples	NULL
were	NULL
from	NULL
donors	NULL
whose	NULL
identity	NULL
was	NULL
unknown	NULL
(	NULL
unlinked	NULL
)	NULL
.	NULL

The	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
samples	NULL
were	NULL
selected	NULL
based	NULL
on	NULL
routine	NULL
phenotyping	NULL
of	NULL
washed	NULL
erythrocytes	NULL
with	NULL
anti-Fy*	NULL
and	NULL
anti-Fy®	NULL
used	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Erythrocytes	NULL
from	NULL
the	NULL
non-Ashkenazi	NULL
Jews	NULL
in	NULL
Israel	NULL
were	NULL
tested	NULL
with	NULL
antiserum	NULL
from	NULL
Gamma	NULL
Biologicals	NULL
Inc	NULL
(	NULL
Houston	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

Erythrocytes	NULL
from	NULL
Brazilian	NULL
blacks	NULL
were	NULL
tested	NULL
with	NULL
antisera	NULL
from	NULL
three	NULL
companies	NULL
(	NULL
Gamma	NULL
Biologicals	NULL
Inc	NULL
;	NULL
Biotest-Sio	NULL
Paulo	NULL
,	NULL
Brazil	NULL
;	NULL
and	NULL
Dia	NULL
Med	NULL
,	NULL
Cressier	NULL
sur	NULL
Morat	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
serological	NULL
testing	NULL
used	NULL
here	NULL
does	NULL
not	NULL
distinguish	NULL
between	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
and	NULL
Fy	NULL
(	NULL
a-b	NULL
``	NULL
***	NULL
)	NULL
erythrocyte	NULL
phenotypes	NULL
.	NULL

Fy	NULL
(	NULL
a-b	NULL
``	NULL
****	NULL
)	NULL
erythrocytes	NULL
often	NULL
type	NULL
as	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
if	NULL
only	NULL
the	NULL
usual	NULL
anti-Fy®	NULL
are	NULL
used	NULL
by	NULL
routine	NULL
methods	NULL
.	NULL

Further	NULL
testing	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
anti-Fy®	NULL
reagents	NULL
as	NULL
well	NULL
as	NULL
a	NULL
quantitative	NULL
adsorption	NULL
and	NULL
elution	NULL
analysis	NULL
have	NULL
to	NULL
be	NULL
performed	NULL
on	NULL
erythrocytes	NULL
identified	NULL
as	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
by	NULL
standard	NULL
agglutination	NULL
assays	NULL
,	NULL
to	NULL
characterize	NULL
such	NULL
samples	NULL
.	NULL

DNA	NULL
was	NULL
prepared	NULL
at	NULL
the	NULL
time	NULL
of	NULL
Fy®	NULL
testing	NULL
and	NULL
by	NULL
the	NULL
time	NULL
that	NULL
analysis	NULL
of	NULL
DNA	NULL
showed	NULL
the	NULL
mutations	NULL
described	NULL
here	NULL
,	NULL
erythrocytes	NULL
were	NULL
not	NULL
available	NULL
for	NULL
further	NULL
testing	NULL
.	NULL

DNA	NULL
preparation	NULL
.	NULL

White	NULL
blood	NULL
cells	NULL
(	NULL
WBCs	NULL
)	NULL
from	NULL
whole	NULL
blood	NULL
were	NULL
obtained	NULL
after	NULL
erythrocyte	NULL
lysis	NULL
with	NULL
a	NULL
solution	NULL
containing	NULL
155	NULL
mmol/L	NULL
NH	NULL
,	NULL
Cl	NULL
,	NULL
10	NULL
mmol/L	NULL
KHCOs	NULL
,	NULL
and	NULL
1.0	NULL
mmol/L	NULL
Na	NULL
;	NULL
-EDTA	NULL
.	NULL

The	NULL
washed	NULL
pellets	NULL
were	NULL
suspended	NULL
in	NULL
buffer	NULL
containing	NULL
10	NULL
mmol/L	NULL
Tris-HCI	NULL
]	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
75	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
24	NULL
mmol/L	NULL
EDTA	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
,	NULL
and	NULL
150	NULL
ug	NULL
proteinase	NULL
K/mL	NULL
,	NULL
and	NULL
kept	NULL
for	NULL
4	NULL
hours	NULL
at	NULL
55°C	NULL
.	NULL

Proteins	NULL
were	NULL
precipitated	NULL
by	NULL
salting	NULL
out	NULL
,	NULL
using	NULL
saturated	NULL
NaCl	NULL
solution	NULL
,	NULL
vigorous	NULL
mixing	NULL
,	NULL
and	NULL
centrifugation	NULL
.	NULL

'*	NULL
The	NULL
supernatants	NULL
were	NULL
mixed	NULL
with	NULL
cold	NULL
ethanol	NULL
.	NULL

The	NULL
precipitated	NULL
DNA	NULL
was	NULL
solubilized	NULL
in	NULL
10	NULL
mmol/L	NULL
Tris-HCI	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
1.0	NULL
mmol/L	NULL
EDTA	NULL
.	NULL

Alternatively	NULL
,	NULL
WBC	NULL
DNA	NULL
was	NULL
extracted	NULL
using	NULL
DNAzo	NULL
!	NULL

Kit	NULL
(	NULL
GIBCO-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

The	NULL
DNA	NULL
solutions	NULL
were	NULL
analyzed	NULL
for	NULL
quality	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
and	NULL
for	NULL
quantity	NULL
by	NULL
optical	NULL
density	NULL
measurements	NULL
at	NULL
260	NULL
nm	NULL
.	NULL

DNA	NULL
amplification	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
using	NULL
100	NULL
to	NULL
200	NULL
ng	NULL
of	NULL
DNA	NULL
,	NULL
3	NULL
pmol	NULL
of	NULL
each	NULL
primer	NULL
,	NULL
2	NULL
nmol	NULL
of	NULL
each	NULL
dNTP	NULL
,	NULL
1.0	NULL
U	NULL
Taq	NULL
polymerase	NULL
and	NULL
buffer	NULL
(	NULL
Perkin	NULL
Elmer	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
,	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
40	NULL
uL	NULL
.	NULL

The	NULL
primers	NULL
used	NULL
for	NULL
PCR	NULL
amplification	NULL
,	NULL
FY3	NULL
,	NULL
5'-CCCTCTTGTGTCCCTCCCTTT	NULL
,	NULL
located	NULL
at	NULL
-276	NULL
-	NULL
-256	NULL
,	NULL
and	NULL
FY4	NULL
,	NULL
5-CAGAGCTGCGAGTGCTACCTA	NULL
,	NULL
located	NULL
at	NULL
385	NULL
-	NULL
365	NULL
,	NULL
were	NULL
designed	NULL
to	NULL
encompass	NULL
the	NULL
coding	NULL
region	NULL
containing	NULL
nt	NULL
131	NULL
(	NULL
site	NULL
for	NULL
FY*A/FY*B	NULL
polymorphism®	NULL
``	NULL
©	NULL
)	NULL
,	NULL
nt	NULL
271	NULL
(	NULL
site	NULL
of	NULL
novel	NULL
mutation	NULL
described	NULL
here	NULL
)	NULL
,	NULL
and	NULL
nt	NULL
304	NULL
(	NULL
site	NULL
of	NULL
mutation	NULL
previously	NULL
described*	NULL
``	NULL
``	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
performed	NULL
in	NULL
an	NULL
automated	NULL
thermal	NULL
cycler	NULL
(	NULL
PTC	NULL
100	NULL
MJ	NULL
Research	NULL
,	NULL
Watertown	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
with	NULL
denaturation	NULL
at	NULL
94°C	NULL
for	NULL
4	NULL
minutes	NULL
,	NULL
followed	NULL
by	NULL
30	NULL
cycles	NULL
of	NULL
amplification	NULL
(	NULL
94°C	NULL
,	NULL
1	NULL
minute	NULL
;	NULL
60°C	NULL
,	NULL
1	NULL
minute	NULL
;	NULL
72°C	NULL
,	NULL
1	NULL
minute	NULL
)	NULL
and	NULL
a	NULL
final	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
10	NULL
minutes	NULL
.	NULL

A	NULL
second	NULL
PCR	NULL
amplification	NULL
of	NULL
a	NULL
DNA	NULL
segment	NULL
containing	NULL
the	NULL
GATA	NULL
mutation	NULL
PARASOL	NULL
ET	NULL
AL	NULL
site	NULL
(	NULL
nt	NULL
-46	NULL
)	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
published	NULL
conditions	NULL
and	NULL
primers	NULL
P38	NULL
and	NULL
P39	NULL
(	NULL
here	NULL
named	NULL
FY1	NULL
and	NULL
FY2	NULL
)	NULL
.	NULL

RFLP	NULL
analysis	NULL
of	NULL
PCR	NULL
products	NULL
.	NULL

-	NULL
The	NULL
restriction	NULL
enzymes	NULL
,	NULL
buffers	NULL
,	NULL
and	NULL
details	NULL
for	NULL
their	NULL
use	NULL
were	NULL
supplied	NULL
by	NULL
New	NULL
England	NULL
BioLabs	NULL
(	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

For	NULL
the	NULL
identification	NULL
of	NULL
FY*A	NULL
and	NULL
FY*B	NULL
,	NULL
15	NULL
uL	NULL
of	NULL
the	NULL
PCR	NULL
product	NULL
(	NULL
DNA	NULL
amplified	NULL
by	NULL
the	NULL
FY3	NULL
and	NULL
FY4	NULL
primers	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
Ban	NULL
I	NULL
.	NULL

The	NULL
restriction	NULL
fragments	NULL
were	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

For	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
GATA	NULL
mutation	NULL
,	NULL
25	NULL
uL	NULL
of	NULL
the	NULL
PCR	NULL
product	NULL
(	NULL
DNA	NULL
amplified	NULL
by	NULL
the	NULL
FY1	NULL
and	NULL
FY2	NULL
primers	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
Sty	NULL
I	NULL
,	NULL
followed	NULL
by	NULL
electrophoresis	NULL
on	NULL
12	NULL
%	NULL
acrylamide	NULL
gel	NULL
.	NULL

For	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
271C	NULL
-	NULL
>	NULL
T	NULL
mutation	NULL
,	NULL
10	NULL
uL	NULL
of	NULL
the	NULL
PCR	NULL
product	NULL
(	NULL
DNA	NULL
amplified	NULL
by	NULL
the	NULL
FY3	NULL
and	NULL
FY4	NULL
primers	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
Act	NULL
I	NULL
,	NULL
and	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
304G	NULL
-	NULL
A	NULL
mutation	NULL
,	NULL
10	NULL
uL	NULL
of	NULL
the	NULL
same	NULL
PCR	NULL
product	NULL
was	NULL
digested	NULL
with	NULL
Mwo	NULL
I	NULL
.	NULL

The	NULL
restriction	NULL
fragments	NULL
were	NULL
resolved	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
analysis	NULL
.	NULL

-	NULL
The	NULL
PCR-amplified	NULL
fragments	NULL
were	NULL
sequenced	NULL
on	NULL
both	NULL
strands	NULL
by	NULL
thermocycling	NULL
sequencing	NULL
with	NULL
automatic	NULL
377	NULL
DNA	NULL
sequencer	NULL
(	NULL
Perkin	NULL
Elmer	NULL
)	NULL
.	NULL

For	NULL
the	NULL
initial	NULL
sample	NULL
that	NULL
showed	NULL
the	NULL
discrepancy	NULL
between	NULL
the	NULL
phenotype	NULL
and	NULL
genotype	NULL
determined	NULL
by	NULL
Ban	NULL
|	NULL
and	NULL
Sty	NULL
I	NULL
[	NULL
phenotype	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
,	NULL
and	NULL
genotype	NULL
FY*B/FY*B-46T	NULL
-	NULL
C	NULL
,	NULL
ie	NULL
,	NULL
being	NULL
only	NULL
heterozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
]	NULL
,	NULL
sequencing	NULL
was	NULL
carried	NULL
out	NULL
between	NULL
nt	NULL
-276	NULL
to	NULL
nt	NULL
1944	NULL
,	NULL
on	NULL
overlapping	NULL
DNA	NULL
fragments	NULL
,	NULL
amplified	NULL
by	NULL
several	NULL
primers	NULL
.	NULL

After	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
271C	NULL
-	NULL
T	NULL
and	NULL
304G	NULL
-	NULL
A	NULL
mutations	NULL
,	NULL
other	NULL
samples	NULL
were	NULL
sequenced	NULL
using	NULL
FY3	NULL
for	NULL
the	NULL
PCR	NULL
products	NULL
generated	NULL
by	NULL
FY3	NULL
and	NULL
FY4	NULL
.	NULL

RESULTS	NULL
Alleles	NULL
FY*A	NULL
and	NULL
FY*B	NULL
in	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotypes	NULL
among	NULL
non-Ashkenazi	NULL
Jews	NULL
.	NULL

-	NULL
Although	NULL
the	NULL
phenotype	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
is	NULL
known	NULL
to	NULL
be	NULL
present	NULL
in	NULL
about	NULL
20	NULL
%	NULL
of	NULL
Jews	NULL
from	NULL
Yemen	NULL
and	NULL
has	NULL
also	NULL
been	NULL
observed	NULL
among	NULL
other	NULL
non-Ashkenazi	NULL
Jews	NULL
,	NULL
'*	NULL
``	NULL
there	NULL
is	NULL
no	NULL
published	NULL
information	NULL
on	NULL
the	NULL
genotypes	NULL
among	NULL
these	NULL
ethnic	NULL
groups	NULL
.	NULL

Using	NULL
the	NULL
Ban	NULL
I	NULL
RFLP	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
FY*A	NULL
and	NULL
FY*B	NULL
alleles	NULL
,	NULL
``	NULL
we	NULL
analyzed	NULL
the	NULL
DNA	NULL
samples	NULL
of	NULL
unrelated	NULL
individuals	NULL
having	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
and	NULL
Fy	NULL
(	NULL
a+	NULL
b-	NULL
)	NULL
phenotypes	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
phenotypes	NULL
,	NULL
we	NULL
found	NULL
FY*A/FY*A	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
and	NULL
FY*A/FY*B	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
)	NULL
;	NULL
the	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotypes	NULL
were	NULL
found	NULL
to	NULL
be	NULL
FY*B/FY*B	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
Ban	NULL
I	NULL
restriction	NULL
patterns	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
indicate	NULL
that	NULL
the	NULL
FY*B	NULL
allele	NULL
is	NULL
the	NULL
silent	NULL
one	NULL
in	NULL
the	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
samples	NULL
from	NULL
non-Ashkenazi	NULL
Jews	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
for	NULL
the	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotypes	NULL
in	NULL
the	NULL
black	NULL
populations	NULL
.	NULL

!	NULL
``	NULL

The	NULL
GATA	NULL
mutation	NULL
in	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
,	NULL
FY*B	NULL
non-Ashkenazi	NULL
Jews	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
GATA	NULL
mutation	NULL
,	NULL
identified	NULL
in	NULL
the	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
black	NULL
population	NULL
,	NULL
``	NULL
``	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
among	NULL
the	NULL
non-Ashkenazi	NULL
Jews	NULL
,	NULL
Sty	NULL
I	NULL
RFLP	NULL
``	NULL
were	NULL
performed	NULL
on	NULL
PCR-amplified	NULL
genomic	NULL
DNA	NULL
from	NULL
samples	NULL
of	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*A	NULL
,	NULL
and	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
(	NULL
genotypes	NULL
as	NULL
identified	NULL
by	NULL
Ban	NULL
I	NULL
)	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
2	NULL
,	NULL
the	NULL
Sty	NULL
I	NULL
RFLP	NULL
identifies	NULL
samples	NULL
that	NULL
are	NULL
homozygous	NULL
and	NULL
heterozygous	NULL
for	NULL
the	NULL
mutation	NULL
,	NULL
with	NULL
several	NULL
samples	NULL
that	NULL
exhibit	NULL
discrepancy	NULL
between	NULL
their	NULL
phenotypes	NULL
and	NULL
genotypes	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
Ban	NULL
I	NULL
and	NULL
Sty	NULL
I	NULL
RFLPs	NULL
(	NULL
genotypes	NULL
of	NULL
samples	NULL
shown	NULL
in	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
7	NULL
corresponded	NULL
to	NULL
their	NULL
phenotypes	NULL
;	NULL
genotypes	NULL
of	NULL
samples	NULL
shown	NULL
in	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
did	NULL
not	NULL
correspond	NULL
to	NULL
their	NULL
phenotypes	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
among	NULL
16	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
individuals	NULL
,	NULL
the	NULL
genotype	NULL
corresponded	NULL
to	NULL
the	NULL
phenotype	NULL
in	NULL
12	NULL
;	NULL
6	NULL
individuals	NULL
were	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
,	NULL
FY*B/	NULL
FY*B	NULL
by	NULL
Ban	NULL
I	NULL
and	NULL
homozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
;	NULL
4	NULL
individuals	NULL
were	NULL
Fy	NULL
(	NULL
a+	NULL
b-	NULL
)	NULL
,	NULL
FY*A/FY*B	NULL
by	NULL
Ban	NULL
I	NULL
and	NULL
heterozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
;	NULL
and	NULL
2	NULL
were	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
,	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

NOVEL	NULL
MUTATION	NULL
IN	NULL
DARC	NULL
ASSOCIATED	NULL
WITH	NULL
ALTERED	NULL
PHENOTYPE	NULL
2239	NULL
A	NULL
Ban	NULL
||	NULL
,	NULL
l	NULL
|	NULL
FY*A	NULL
allele	NULL
}	NULL
52	NULL
bp	NULL
353	NULL
bp	NULL
212	NULL
bp	NULL
|44	NULL
bp	NULL
FY*B	NULL
allele	NULL
52	NULL
bp	NULL
565	NULL
bp	NULL
44	NULL
bp	NULL
Fig	NULL
1	NULL
.	NULL

Ban	NULL
|	NULL
RFLP	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
FY*	NULL
A	NULL
and	NULL
FY*B	NULL
alleles	NULL
in	NULL
non-Ashkenazi	NULL
Jews	NULL
.	NULL

DNA	NULL
was	NULL
amplified	NULL
using	NULL
FY3	NULL
and	NULL
FY4	NULL
primers	NULL
for	NULL
the	NULL
amplification	NULL
of	NULL
a	NULL
DARC	NULL
fragment	NULL
containing	NULL
the	NULL
131G	NULL
-	NULL
>	NULL
A	NULL
substitution	NULL
,	NULL
responsible	NULL
for	NULL
FY*	NULL
A	NULL
and	NULL
FY*	NULL
B	NULL
,	NULL
respec-tively	NULL
.	NULL

Restriction	NULL
fragments	NULL
were	NULL
separated	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
fragments	NULL
generated	NULL
by	NULL
the	NULL
Ban	NULL
I	NULL
digestion	NULL
of	NULL
FY*A	NULL
and	NULL
FY*B	NULL
DNA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RFLP	NULL
patterns	NULL
of	NULL
DNA	NULL
from	NULL
samples	NULL
with	NULL
the	NULL
indicated	NULL
phenotypes	NULL
,	NULL
identified	NULL
by	NULL
antisera	NULL
(	NULL
the	NULL
52-	NULL
and	NULL
44-bp	NULL
fragments	NULL
are	NULL
not	NULL
detected	NULL
in	NULL
this	NULL
gel	NULL
)	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
,	NULL
100-bp	NULL
ladder	NULL
;	NULL
2	NULL
,	NULL
uncut	NULL
;	NULL
3	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
;	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
,	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
.	NULL

FY*A/FY*A	NULL
by	NULL
Ban	NULL
I	NULL
and	NULL
homozygous	NULL
for	NULL
the	NULL
wild-type	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
4	NULL
individuals	NULL
showed	NULL
a	NULL
discrepancy	NULL
between	NULL
the	NULL
phenotype	NULL
and	NULL
genotype	NULL
:	NULL
2	NULL
individuals	NULL
,	NULL
who	NULL
were	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
,	NULL
FY*B/FY*B	NULL
by	NULL
Ban	NULL
I	NULL
,	NULL
were	NULL
only	NULL
heterozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
,	NULL
and	NULL
two	NULL
individuals	NULL
,	NULL
who	NULL
were	NULL
Fy	NULL
(	NULL
a+	NULL
b-	NULL
)	NULL
,	NULL
FY*A/FY*B	NULL
by	NULL
Ban	NULL
I	NULL
,	NULL
were	NULL
homozygous	NULL
for	NULL
wild-type	NULL
pro-moter	NULL
,	NULL
ie	NULL
,	NULL
lacked	NULL
the	NULL
GATA	NULL
mutation	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
A	NULL
Sty	NULL
|	NULL
J	NULL
|	NULL
in	NULL
some	NULL
of	NULL
the	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
FY*B	NULL
individuals	NULL
among	NULL
the	NULL
non-Ashkenazi	NULL
Jews	NULL
,	NULL
some	NULL
mutation	NULL
(	NULL
s	NULL
)	NULL
other	NULL
than	NULL
the	NULL
GATA	NULL
mutation	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
erythrocyte	NULL
``	NULL
silent	NULL
``	NULL
FY*B	NULL
.	NULL

Identification	NULL
of	NULL
mutations	NULL
at	NULL
nucleotides	NULL
271	NULL
and	NULL
304	NULL
.	NULL

DNA	NULL
from	NULL
the	NULL
first	NULL
discordant	NULL
sample	NULL
,	NULL
identified	NULL
as	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
and	NULL
heterozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
,	NULL
was	NULL
sequenced	NULL
and	NULL
found	NULL
to	NULL
have	NULL
two	NULL
mutations	NULL
in	NULL
the	NULL
coding	NULL
U	NULL
GATA	NULL
box	NULL
mutant	NULL
(	NULL
-46	NULL
T-C	NULL
)	NULL
|	NULL
__	NULL
82	NULL
bp	NULL
___	NULL
[	NULL
12	NULL
]	NULL
ia	NULL
GATA	NULL
box	NULL
-	NULL
wild	NULL
type	NULL
[	NULL
__	NULL
82	NULL
bp	NULL
__|	NULL
77	NULL
bp	NULL
_|	NULL
62	NULL
bp	NULL
_|	NULL
Fig	NULL
2	NULL
.	NULL

Sty	NULL
|	NULL
RFLP	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
GATA	NULL
mutation	NULL
(	NULL
-46	NULL
T	NULL
-	NULL
>	NULL
C	NULL
)	NULL
.	NULL

DNA	NULL
was	NULL
amplified	NULL
using	NULL
FY1	NULL
and	NULL
FY2	NULL
primers	NULL
!	NULL

for	NULL
the	NULL
amplification	NULL
of	NULL
a	NULL
DARC	NULL
fragment	NULL
encompassing	NULL
nt	NULL
-46	NULL
.	NULL

The	NULL
restriction	NULL
fragments	NULL
were	NULL
separated	NULL
on	NULL
12	NULL
%	NULL
acrylamide	NULL
gel	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
fragments	NULL
generated	NULL
by	NULL
Sty	NULL
|	NULL
digestion	NULL
of	NULL
the	NULL
DARC	NULL
fragment	NULL
encompassing	NULL
nt	NULL
-46	NULL
FY*B	NULL
,	NULL
GATA	NULL
mutation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RFLP	NULL
patterns	NULL
of	NULL
DNA	NULL
from	NULL
samples	NULL
with	NULL
the	NULL
indicated	NULL
phenotyes	NULL
,	NULL
identified	NULL
by	NULL
antisera	NULL
,	NULL
and	NULL
genotypes	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
Ban	NULL
|	NULL
(	NULL
the	NULL
12-bp	NULL
fragment	NULL
is	NULL
not	NULL
detected	NULL
in	NULL
this	NULL
gel	NULL
)	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
4	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*	NULL
A/	NULL
FY*	NULL
A	NULL
;	NULL
3	NULL
and	NULL
7	NULL
,	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
;	NULL
5	NULL
and	NULL
6	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*	NULL
A/FY*	NULL
B	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2240	NULL
Table	NULL
1	NULL
.	NULL

Duffy	NULL
Phenotypes	NULL
and	NULL
Genotypes	NULL
in	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
Non-Ashkenazi	NULL
Jew	NULL
s	NULL
Phenotype	NULL
Genotype	NULL
Genotype	NULL
-	NULL
Genotype	NULL
Genotype	NULL
Samples	NULL
_	NULL
-	NULL
FY*A	NULL
,	NULL
FY*B	NULL
_	NULL
FY	NULL
,	NULL
FY¢	NULL
-	NULL
271	NULL
(	NULL
C-	NULL
T	NULL
)	NULL
304	NULL
(	NULL
G-	NULL
A	NULL
)	NULL
(	NULL
n	NULL
=	NULL
16	NULL
)	NULL
_	NULL
[	NULL
Anti-Fyb	NULL
]	NULL
[	NULL
Ban	NULL
\t	NULL
[	NULL
Sty	NULL
IIt	NULL
[	NULL
Acillt	NULL
[	NULL
Mwo	NULL
6	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
-	NULL
FY/FY-	NULL
CIC	NULL
G/G	NULL
2	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
_	NULL
FV/FY-	NULL
TC	NULL
AG	NULL
4	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
_	NULL
FV/FY-	NULL
CIC	NULL
G/G	NULL
2	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
_	NULL
FV/FY	NULL
TC	NULL
AG	NULL
2	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*A	NULL
_	NULL
FV/FY	NULL
CIC	NULL
G/G	NULL
T	NULL
[	NULL
]	NULL
,	NULL
Identified	NULL
by	NULL
antisera	NULL
,	NULL
by	NULL
restriction	NULL
enzymes	NULL
.	NULL

{	NULL
FY	NULL
,	NULL
wild-type	NULL
GATA	NULL
;	NULL
FY-	NULL
,	NULL
GATA	NULL
mutation	NULL
.	NULL

sequence	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
wild	NULL
FY*B	NULL
allele	NULL
.	NULL
``	NULL

The	NULL
first	NULL
one	NULL
was	NULL
a	NULL
novel	NULL
mutation	NULL
of	NULL
C	NULL
-	NULL
T	NULL
at	NULL
nucleotide	NULL
271	NULL
(	NULL
271€C	NULL
-	NULL
T	NULL
)	NULL
and	NULL
the	NULL
second	NULL
one	NULL
was	NULL
a	NULL
previously	NULL
described	NULL
mutation	NULL
of	NULL
G	NULL
-	NULL
A	NULL
at	NULL
nucleotide	NULL
304	NULL
(	NULL
304G	NULL
-	NULL
A	NULL
)	NULL
.	NULL
``	NULL

Based	NULL
on	NULL
these	NULL
mutations	NULL
,	NULL
PCR-RFLP	NULL
were	NULL
developed	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
mutations	NULL
,	NULL
Act	NULL
I	NULL
RFLP	NULL
for	NULL
271C	NULL
-	NULL
T	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
and	NULL
Mwo	NULL
I	NULL
RFLP	NULL
for	NULL
304G	NULL
-	NULL
A	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
all	NULL
four	NULL
individuals	NULL
,	NULL
whose	NULL
GATA	NULL
genotypes	NULL
did	NULL
not	NULL
correspond	NULL
to	NULL
their	NULL
phenotypes	NULL
were	NULL
found	NULL
to	NULL
be	NULL
heterozygous	NULL
for	NULL
both	NULL
mutations	NULL
.	NULL

The	NULL
mutations	NULL
detected	NULL
by	NULL
RFLP	NULL
using	NULL
Aci	NULL
I	NULL
and	NULL
Mwo	NULL
I	NULL
were	NULL
further	NULL
confirmed	NULL
by	NULL
sequencing	NULL
the	NULL
PCR-amplified	NULL
DNA	NULL
of	NULL
these	NULL
samples	NULL
.	NULL

The	NULL
simultaneous	NULL
presence	NULL
of	NULL
the	NULL
271C	NULL
-	NULL
T	NULL
and	NULL
304G	NULL
-	NULL
A	NULL
in	NULL
the	NULL
discordant	NULL
cases	NULL
implies	NULL
that	NULL
these	NULL
mutations	NULL
are	NULL
responsible	NULL
for	NULL
some	NULL
cases	NULL
of	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
,	NULL
wild-type	NULL
GATA	NULL
erythrocytes	NULL
among	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
non-Ashkenazi	NULL
Jews	NULL
.	NULL

A	NULL
Acil	NULL
l	NULL
PARASOL	NULL
ET	NULL
AL	NULL
Identification	NULL
of	NULL
the	NULL
2710	NULL
-	NULL
T	NULL
and	NULL
304G	NULL
-	NULL
A	NULL
mutations	NULL
among	NULL
Brazilian	NULL
black	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
individuals	NULL
.	NULL

Thirty-four	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
and	NULL
15	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
samples	NULL
from	NULL
Brazilian	NULL
black	NULL
people	NULL
were	NULL
analyzed	NULL
for	NULL
FY*A	NULL
and	NULL
FY*B	NULL
alleles	NULL
,	NULL
using	NULL
the	NULL
Ban	NULL
I	NULL
RFLP	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
,	NULL
all	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotypes	NULL
were	NULL
homozygous	NULL
for	NULL
the	NULL
FY*B	NULL
allele	NULL
.	NULL

Among	NULL
the	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
,	NULL
3	NULL
were	NULL
homozygous	NULL
for	NULL
FY*A	NULL
and	NULL
12	NULL
were	NULL
heterozygous	NULL
,	NULL
FY*A/FY*B	NULL
.	NULL

These	NULL
results	NULL
correspond	NULL
to	NULL
those	NULL
observed	NULL
in	NULL
other	NULL
studies	NULL
on	NULL
black	NULL
populations	NULL
,	NULL
?	NULL

in	NULL
which	NULL
homozygosity	NULL
for	NULL
the	NULL
FY*B	NULL
allele	NULL
was	NULL
found	NULL
in	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
,	NULL
and	NULL
homozygosity	NULL
for	NULL
FY*A	NULL
or	NULL
heterozygosity	NULL
for	NULL
FY*A/FY*B	NULL
was	NULL
shown	NULL
in	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
Ban	NULL
I	NULL
RFLP	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
49	NULL
samples	NULL
with	NULL
Sty	NULL
I	NULL
showed	NULL
that	NULL
33	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/	NULL
FY*B	NULL
were	NULL
homozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
;	NULL
thus	NULL
,	NULL
their	NULL
phenotype	NULL
can	NULL
be	NULL
accounted	NULL
for	NULL
by	NULL
the	NULL
GATA	NULL
mutation	NULL
.	NULL

One	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/	NULL
FY*B	NULL
individual	NULL
was	NULL
heterozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
,	NULL
thus	NULL
showing	NULL
a	NULL
discrepancy	NULL
between	NULL
his	NULL
phenotype	NULL
and	NULL
genotype	NULL
.	NULL

Among	NULL
the	NULL
15	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
individuals	NULL
,	NULL
the	NULL
FY	NULL
and	NULL
GATA	NULL
genotypes	NULL
corresponded	NULL
to	NULL
their	NULL
phenotypes	NULL
in	NULL
12	NULL
:	NULL
as	NULL
expected	NULL
,	NULL
the	NULL
three	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*A	NULL
had	NULL
the	NULL
wild-type	NULL
GATA	NULL
and	NULL
9	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
were	NULL
heterozygous	NULL
for	NULL
the	NULL
GATA	NULL
mutation	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
three	NULL
individuals	NULL
,	NULL
who	NULL
were	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
,	NULL
wild-type	NULL
GATA	NULL
was	NULL
found	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
four	NULL
individuals	NULL
of	NULL
the	NULL
49	NULL
analyzed	NULL
,	NULL
their	NULL
Duffy	NULL
phenotypes	NULL
and	NULL
genotypes	NULL
could	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
FY	NULL
and	NULL
GATA	NULL
genotyping	NULL
.	NULL

RFLP	NULL
analysis	NULL
by	NULL
Aci	NULL
I	NULL
and	NULL
Mwo	NULL
I	NULL
showed	NULL
that	NULL
all	NULL
four	NULL
individuals	NULL
were	NULL
heterozygous	NULL
for	NULL
both	NULL
the	NULL
271C	NULL
-	NULL
T	NULL
mutation	NULL
and	NULL
the	NULL
304G	NULL
-	NULL
A	NULL
mutation	NULL
.	NULL

These	NULL
two	NULL
mutations	NULL
were	NULL
not	NULL
found	NULL
in	NULL
the	NULL
other	NULL
45	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
individuals	NULL
,	NULL
in	NULL
whom	NULL
the	NULL
genotype	NULL
271	NULL
wild	NULL
type	NULL
164	NULL
bp	NULL
|	NULL
139	NULL
bp	NULL
242	NULL
bp	NULL
|116	NULL
bp	NULL
271	NULL
mutant	NULL
(	NULL
C	NULL
--	NULL
>	NULL
T	NULL
)	NULL
164	NULL
bp	NULL
|	NULL
139	NULL
bp	NULL
358	NULL
bp	NULL
Fig	NULL
3	NULL
.	NULL

Acil	NULL
RFLP	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
271C	NULL
-	NULL
T	NULL
mutation	NULL
.	NULL

DNA	NULL
was	NULL
amplified	NULL
using	NULL
the	NULL
FY3	NULL
and	NULL
FY4	NULL
primers	NULL
.	NULL

Restriction	NULL
fragments	NULL
were	NULL
separated	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
fragments	NULL
generated	NULL
by	NULL
Aci	NULL
|	NULL
digestion	NULL
of	NULL
the	NULL
DARC	NULL
fragment	NULL
encompassing	NULL
nt	NULL
271	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RFLP	NULL
patterns	NULL
of	NULL
DNA	NULL
from	NULL
samples	NULL
with	NULL
the	NULL
indicated	NULL
phenotypes	NULL
,	NULL
identified	NULL
by	NULL
antisera	NULL
,	NULL
and	NULL
genotypes	NULL
,	NULL
determined	NULL
by	NULL
Ban	NULL
I	NULL
and	NULL
Sty	NULL
|	NULL
(	NULL
FY*B	NULL
=	NULL
wild-type	NULL
GATA	NULL
;	NULL
FY*	NULL
B-	NULL
=	NULL
GATA	NULL
mutation	NULL
)	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
through	NULL
3	NULL
,	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B-/FY*B-	NULL
;	NULL
4	NULL
,	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*	NULL
B/FY*	NULL
B-	NULL
;	NULL
5	NULL
through	NULL
7	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B-	NULL
;	NULL
8	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

NOVEL	NULL
MUTATION	NULL
IN	NULL
DARC	NULL
ASSOCIATED	NULL
WITH	NULL
ALTERED	NULL
PHENOTYPE	NULL
A	NULL
Mwo	NULL
|	NULL
304	NULL
wild	NULL
type	NULL
304	NULL
mutant	NULL
(	NULL
G-A	NULL
)	NULL
Fig	NULL
4	NULL
.	NULL

Mwo	NULL
|	NULL
RFLP	NULL
for	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
304G	NULL
-	NULL
A	NULL
mutation	NULL
.	NULL

DNA	NULL
was	NULL
amplified	NULL
using	NULL
the	NULL
FY3	NULL
and	NULL
FY4	NULL
primers	NULL
.	NULL

B	NULL
Restriction	NULL
fragments	NULL
w	NULL
ere	NULL
separated	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
fragments	NULL
generated	NULL
by	NULL
Mwo	NULL
I	NULL
digestion	NULL
of	NULL
the	NULL
DARC	NULL
fragment	NULL
encompass	NULL
ing	NULL
nt	NULL
304	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RFLP	NULL
patterns	NULL
of	NULL
DNA	NULL
from	NULL
samples	NULL
with	NULL
the	NULL
indicated	NULL
phenotypes	NULL
,	NULL
identified	NULL
by	NULL
antisera	NULL
,	NULL
and	NULL
genotypes	NULL
,	NULL
determined	NULL
by	NULL
Ban	NULL
|	NULL
and	NULL
Sty	NULL
1	NULL
(	NULL
FY*B	NULL
=	NULL
wild-type	NULL
GATA	NULL
;	NULL
FY*B-	NULL
=	NULL
GATA	NULL
mutation	NULL
)	NULL
.	NULL

Lanes	NULL
:	NULL
1	NULL
and	NULL
2	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
;	NULL
3	NULL
and	NULL
8	NULL
,	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*	NULL
B/FY*B-	NULL
;	NULL
4	NULL
and	NULL
5	NULL
,	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*	NULL
A/FY*B-	NULL
;	NULL
6	NULL
and	NULL
7	NULL
,	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B-/FY*	NULL
B-	NULL
.	NULL

corresponded	NULL
to	NULL
the	NULL
phenotype	NULL
according	NULL
to	NULL
the	NULL
FY	NULL
and	NULL
GATA	NULL
analysis	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
,	NULL
as	NULL
in	NULL
non-Ashkenazi	NULL
Jews	NULL
,	NULL
an	NULL
FY*B	NULL
mutation	NULL
different	NULL
from	NULL
the	NULL
common	NULL
GATA	NULL
mutation	NULL
in	NULL
black	NULL
populations	NULL
is	NULL
also	NULL
associated	NULL
with	NULL
some	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotypes	NULL
among	NULL
the	NULL
Brazilian	NULL
blacks	NULL
.	NULL

The	NULL
findings	NULL
indicate	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
mutations	NULL
result	NULL
in	NULL
an	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
.	NULL

DISCUSSION	NULL
We	NULL
describe	NULL
here	NULL
a	NULL
novel	NULL
mutation	NULL
in	NULL
the	NULL
FY*B	NULL
allele	NULL
of	NULL
the	NULL
Duffy	NULL
chemokine	NULL
receptor	NULL
gene	NULL
.	NULL

This	NULL
mutation	NULL
,	NULL
together	NULL
with	NULL
a	NULL
previously	NULL
described	NULL
mutation	NULL
,	NULL
results	NULL
in	NULL
erythrocyte	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
as	NULL
identified	NULL
by	NULL
standard	NULL
agglutination	NULL
assays	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
phenotype	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
,	NULL
similarly	NULL
identified	NULL
by	NULL
standard	NULL
reagents	NULL
,	NULL
is	NULL
present	NULL
in	NULL
about	NULL
70	NULL
%	NULL
of	NULL
both	NULL
American	NULL
blacks	NULL
``	NULL
and	NULL
Brazilian	NULL
blacks	NULL
,	NULL
``	NULL
``	NULL
and	NULL
is	NULL
also	NULL
present	NULL
in	NULL
non-Ashkenazi	NULL
Jews	NULL
,	NULL
notably	NULL
in	NULL
about	NULL
20	NULL
%	NULL
of	NULL
Yemenite	NULL
Jews	NULL
.	NULL
``	NULL

''	NULL
The	NULL
promoter	NULL
GATA	NULL
mutation	NULL
in	NULL
the	NULL
FY*B	NULL
allele	NULL
``	NULL
accounts	NULL
for	NULL
the	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
among	NULL
African	NULL
black	NULL
populations	NULL
.	NULL

*	NULL
``	NULL
2	NULL
As	NULL
is	NULL
shown	NULL
here	NULL
,	NULL
the	NULL
same	NULL
mutation	NULL
is	NULL
prevalent	NULL
among	NULL
the	NULL
Brazilian	NULL
blacks	NULL
and	NULL
is	NULL
also	NULL
found	NULL
in	NULL
the	NULL
FY*B	NULL
allele	NULL
among	NULL
Table	NULL
2	NULL
.	NULL

Duffy	NULL
Phenotypes	NULL
and	NULL
Genotypes	NULL
in	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
Brazilian	NULL
Blacks	NULL
Phenotype	NULL
Genotype	NULL
Genotype	NULL
-	NULL
Genotype	NULL
Genotype	NULL
Samples	NULL
|	NULL
[	NULL
Anti-Fy	NULL
``	NULL
t	NULL
-	NULL
FY*A	NULL
,	NULL
FY*B	NULL
_	NULL
FY	NULL
,	NULL
FY¢	NULL
271	NULL
(	NULL
C-	NULL
T	NULL
)	NULL
304	NULL
(	NULL
G-	NULL
A	NULL
)	NULL
{	NULL
n	NULL
=	NULL
49	NULL
)	NULL
_	NULL
[	NULL
Anti-Fy®	NULL
]	NULL
[	NULL
Ban	NULL
I\t	NULL
[	NULL
Sty	NULL
It	NULL
[	NULL
Acilt	NULL
[	NULL
Mwo	NULL
33	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
-	NULL
FY/FY-	NULL
CIC	NULL
G/G	NULL
1	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
FY*B/FY*B	NULL
_	NULL
FV/FY-	NULL
TC	NULL
AG	NULL
9	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
_	NULL
FV/FY-	NULL
CIC	NULL
G/G	NULL
3	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*B	NULL
_	NULL
FV/FY	NULL
TC	NULL
AG	NULL
3	NULL
Fy	NULL
(	NULL
a+b-	NULL
)	NULL
FY*A/FY*A	NULL
_	NULL
FV/FY	NULL
CIC	NULL
G/G	NULL
T	NULL
[	NULL
_	NULL
]	NULL
,	NULL
Identified	NULL
by	NULL
antisera	NULL
,	NULL
by	NULL
restriction	NULL
enzymes	NULL
.	NULL

{	NULL
FY	NULL
,	NULL
wild-type	NULL
GATA	NULL
;	NULL
FY-	NULL
,	NULL
GATA	NULL
mutation	NULL
.	NULL

2241	NULL
W	NULL
I	NULL
e	NULL
451	NULL
bp	NULL
67	NULL
bp	NULL
518	NULL
bp	NULL
-	NULL
518	NULL
bp	NULL
-	NULL
451	NULL
bp	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
non-Ashkenazi	NULL
Jews	NULL
.	NULL

However	NULL
,	NULL
in	NULL
some	NULL
individuals	NULL
there	NULL
appeared	NULL
to	NULL
be	NULL
a	NULL
discrepancy	NULL
between	NULL
their	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
and	NULL
genotype	NULL
,	NULL
with	NULL
a	NULL
discordant	NULL
FY*B	NULL
allele	NULL
having	NULL
the	NULL
promoter	NULL
wild-type	NULL
GATA	NULL
.	NULL

In	NULL
these	NULL
individuals	NULL
,	NULL
two	NULL
mutations	NULL
in	NULL
the	NULL
coding	NULL
sequence	NULL
(	NULL
271C	NULL
-	NULL
T	NULL
and	NULL
304G	NULL
-	NULL
A	NULL
)	NULL
were	NULL
found	NULL
in	NULL
the	NULL
discordant	NULL
FY*B	NULL
allele	NULL
.	NULL

Both	NULL
mutations	NULL
were	NULL
identified	NULL
among	NULL
the	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
FY*B	NULL
non-Ashkenazi	NULL
Jews	NULL
and	NULL
among	NULL
the	NULL
Brazilian	NULL
blacks	NULL
,	NULL
suggesting	NULL
an	NULL
association	NULL
with	NULL
FY*B	NULL
gene	NULL
silencing	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

The	NULL
304G	NULL
-	NULL
A	NULL
mutation	NULL
,	NULL
which	NULL
codes	NULL
for	NULL
Ala	NULL
-	NULL
Thr	NULL
at	NULL
amino	NULL
acid	NULL
residue	NULL
102	NULL
,	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
in	NULL
a	NULL
study	NULL
using	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
-PCR	NULL
of	NULL
placental	NULL
RNA	NULL
as	NULL
a	NULL
source	NULL
for	NULL
cloning	NULL
and	NULL
sequencing	NULL
of	NULL
the	NULL
Duffy	NULL
gene	NULL
.	NULL
``	NULL

In	NULL
another	NULL
study	NULL
,	NULL
the	NULL
same	NULL
mutation	NULL
was	NULL
found	NULL
in	NULL
Fy	NULL
(	NULL
a+	NULL
b+	NULL
)	NULL
and	NULL
Fy	NULL
(	NULL
a+	NULL
b-	NULL
)	NULL
samples	NULL
.	NULL
``	NULL

Based	NULL
on	NULL
these	NULL
studies	NULL
,	NULL
the	NULL
304G	NULL
-	NULL
A	NULL
mutation	NULL
may	NULL
be	NULL
a	NULL
polymorphic	NULL
one	NULL
,	NULL
as	NULL
has	NULL
been	NULL
suggested	NULL
.	NULL

``	NULL
?	NULL

Further	NULL
studies	NULL
are	NULL
required	NULL
to	NULL
establish	NULL
whether	NULL
304G	NULL
-	NULL
A	NULL
is	NULL
a	NULL
polymorphic	NULL
mutation	NULL
,	NULL
whether	NULL
the	NULL
271C	NULL
-	NULL
T	NULL
mutation	NULL
occurred	NULL
in	NULL
this	NULL
variant	NULL
and	NULL
whether	NULL
the	NULL
expression	NULL
of	NULL
both	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
.	NULL

It	NULL
is	NULL
of	NULL
interest	NULL
to	NULL
note	NULL
that	NULL
according	NULL
to	NULL
the	NULL
proposed	NULL
three-dimensional	NULL
structure	NULL
of	NULL
DARC	NULL
(	NULL
involving	NULL
seven	NULL
transmembrane	NULL
segments	NULL
)	NULL
,	NULL
``	NULL
the	NULL
amino	NULL
acid	NULL
102	NULL
(	NULL
amino	NULL
acid	NULL
residue	NULL
according	NULL
to	NULL
Chaudhuri	NULL
et	NULL
al	NULL
``	NULL
;	NULL
residue	NULL
100	NULL
according	NULL
to	NULL
Iwamoto	NULL
et	NULL
al	NULL
``	NULL
)	NULL
would	NULL
be	NULL
in	NULL
the	NULL
second	NULL
transmembrane	NULL
segment	NULL
,	NULL
and	NULL
a	NULL
substitution	NULL
of	NULL
Ala	NULL
-	NULL
Thr	NULL
might	NULL
not	NULL
lead	NULL
to	NULL
more	NULL
than	NULL
a	NULL
modest	NULL
change	NULL
in	NULL
receptor	NULL
properties	NULL
The	NULL
271€C	NULL
-	NULL
T	NULL
mutation	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
converts	NULL
the	NULL
residue	NULL
91	NULL
(	NULL
amino	NULL
acid	NULL
residue	NULL
according	NULL
to	NULL
Chaudhuri	NULL
et	NULL
al	NULL
``	NULL
;	NULL
residue	NULL
89	NULL
according	NULL
to	NULL
Iwamoto	NULL
et	NULL
al	NULL
``	NULL
)	NULL
,	NULL
assumed	NULL
to	NULL
be	NULL
in	NULL
the	NULL
first	NULL
cytoplasmic	NULL
loop	NULL
,	NULL
from	NULL
Arg	NULL
-	NULL
Cys	NULL
.	NULL

This	NULL
substitution	NULL
represents	NULL
a	NULL
considerable	NULL
change	NULL
in	NULL
the	NULL
chemical	NULL
nature	NULL
of	NULL
the	NULL
local	NULL
region	NULL
and	NULL
may	NULL
affect	NULL
the	NULL
behavior	NULL
of	NULL
DARC	NULL
and	NULL
its	NULL
extracellular	NULL
antigenic	NULL
sites	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
a	NULL
combination	NULL
of	NULL
two	NULL
mutations	NULL
within	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

2242	NULL
coding	NULL
sequence	NULL
may	NULL
result	NULL
in	NULL
an	NULL
apparent	NULL
erythrocyte	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
phenotype	NULL
raises	NULL
several	NULL
important	NULL
questions	NULL
.	NULL

The	NULL
promoter	NULL
GATA	NULL
substitution	NULL
,	NULL
which	NULL
impairs	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
erythroid	NULL
transcription	NULL
factor	NULL
and	NULL
results	NULL
in	NULL
a	NULL
silent	NULL
erythroid	NULL
FY*B	NULL
allele	NULL
and	NULL
lack	NULL
of	NULL
erythrocyte	NULL
Duffy	NULL
receptor	NULL
,	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
gene	NULL
in	NULL
other	NULL
cells	NULL
.	NULL

!	NULL
``	NULL

It	NULL
is	NULL
not	NULL
known	NULL
at	NULL
present	NULL
whether	NULL
the	NULL
DARC	NULL
Arg91	NULL
-	NULL
Cys	NULL
,	NULL
Ala102	NULL
Thr	NULL
mutant	NULL
protein	NULL
is	NULL
present	NULL
in	NULL
the	NULL
erythrocyte	NULL
membranes	NULL
.	NULL

The	NULL
point	NULL
mutations	NULL
leading	NULL
to	NULL
amino	NULL
acid	NULL
substitutions	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
allow	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
protein	NULL
,	NULL
albeit	NULL
in	NULL
a	NULL
possibly	NULL
altered	NULL
conformation	NULL
and	NULL
altered	NULL
ligand-binding	NULL
prop-erties	NULL
.	NULL

However	NULL
,	NULL
it	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
that	NULL
such	NULL
mutations	NULL
result	NULL
in	NULL
a	NULL
deficiency	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
eg	NULL
,	NULL
due	NULL
to	NULL
failure	NULL
of	NULL
being	NULL
incorporated	NULL
into	NULL
the	NULL
cell	NULL
membrane	NULL
,	NULL
or	NULL
being	NULL
susceptible	NULL
to	NULL
degradation	NULL
)	NULL
.	NULL

It	NULL
would	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
study	NULL
whether	NULL
this	NULL
DARC	NULL
mutant	NULL
is	NULL
fully	NULL
or	NULL
partially	NULL
expressed	NULL
in	NULL
or	NULL
absent	NULL
from	NULL
erythrocytes	NULL
and	NULL
from	NULL
other	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
because	NULL
the	NULL
spliced	NULL
transcript	NULL
may	NULL
normally	NULL
be	NULL
the	NULL
predominant	NULL
one	NULL
,	NULL
``	NULL
it	NULL
may	NULL
be	NULL
relevant	NULL
to	NULL
find	NULL
out	NULL
whether	NULL
there	NULL
is	NULL
any	NULL
preferential	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
one	NULL
of	NULL
the	NULL
two	NULL
transcripts	NULL
``	NULL
in	NULL
the	NULL
mutant	NULL
cells	NULL
.	NULL

In	NULL
any	NULL
case	NULL
,	NULL
the	NULL
overall	NULL
phenotype	NULL
of	NULL
the	NULL
mutant	NULL
described	NULL
here	NULL
is	NULL
expected	NULL
to	NULL
be	NULL
different	NULL
from	NULL
the	NULL
GATA	NULL
mutation	NULL
,	NULL
because	NULL
both	NULL
the	NULL
erythrocytes	NULL
and	NULL
other	NULL
DARC	NULL
expressing	NULL
cells	NULL
would	NULL
be	NULL
affected	NULL
by	NULL
mutations	NULL
in	NULL
the	NULL
coding	NULL
sequence	NULL
that	NULL
alter	NULL
the	NULL
expression	NULL
and/or	NULL
ligand-binding	NULL
properties	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Additional	NULL
studies	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
anti-Fy	NULL
``	NULL
®	NULL
,	NULL
including	NULL
quantitative	NULL
titrations	NULL
of	NULL
antibody	NULL
binding	NULL
,	NULL
are	NULL
necessary	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
mutant	NULL
erythrocytes	NULL
described	NULL
here	NULL
behave	NULL
as	NULL
a	NULL
Fy	NULL
(	NULL
b****	NULL
)	NULL
variant	NULL
.	NULL

It	NULL
may	NULL
be	NULL
important	NULL
to	NULL
define	NULL
the	NULL
properties	NULL
of	NULL
the	NULL
mutant	NULL
erythrocytes	NULL
and	NULL
other	NULL
DARC-expressing	NULL
cells	NULL
for	NULL
binding	NULL
malarial	NULL
parasites	NULL
and	NULL
chemokines	NULL
.	NULL

It	NULL
should	NULL
also	NULL
be	NULL
pointed	NULL
out	NULL
that	NULL
chemokine	NULL
binding	NULL
to	NULL
DARC	NULL
has	NULL
characteristics	NULL
different	NULL
from	NULL
those	NULL
of	NULL
antibody	NULL
binding	NULL
,	NULL
``	NULL
and	NULL
that	NULL
differences	NULL
exist	NULL
among	NULL
various	NULL
chemokines	NULL
in	NULL
their	NULL
interaction	NULL
with	NULL
DARC	NULL
.	NULL
``	NULL

''	NULL
Thus	NULL
,	NULL
DARC	NULL
mutant	NULL
erythrocytes	NULL
that	NULL
do	NULL
not	NULL
bind	NULL
anti-Fy	NULL
``	NULL
may	NULL
nevertheless	NULL
react	NULL
with	NULL
chemokines	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
roles	NULL
of	NULL
DARC	NULL
in	NULL
various	NULL
tissues	NULL
are	NULL
not	NULL
known	NULL
at	NULL
present	NULL
,	NULL
the	NULL
properties	NULL
of	NULL
a	NULL
mutant	NULL
such	NULL
as	NULL
the	NULL
one	NULL
described	NULL
here	NULL
may	NULL
be	NULL
of	NULL
physiological	NULL
significance	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
Duffy	NULL
blood	NULL
group	NULL
system	NULL
in	NULL
clinical	NULL
medicine	NULL
,	NULL
eg	NULL
,	NULL
in	NULL
cases	NULL
of	NULL
transfusion	NULL
incompatibility	NULL
and	NULL
hemolytic	NULL
disease	NULL
of	NULL
the	NULL
new	NULL
born	NULL
,	NULL
***	NULL
in	NULL
forensic	NULL
medicine	NULL
,	NULL
and	NULL
in	NULL
malaria	NULL
epidemiology	NULL
,	NULL
screening	NULL
procedures	NULL
are	NULL
being	NULL
developed	NULL
for	NULL
detection	NULL
of	NULL
the	NULL
known	NULL
common	NULL
variants	NULL
and	NULL
mutations	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
The	NULL
restriction	NULL
enzyme-generated	NULL
RFLPs	NULL
described	NULL
here	NULL
provide	NULL
a	NULL
means	NULL
for	NULL
screening	NULL
samples	NULL
for	NULL
the	NULL
271C	NULL
-	NULL
T	NULL
and	NULL
the	NULL
304G	NULL
-	NULL
A	NULL
.	NULL

Screening	NULL
for	NULL
these	NULL
mutations	NULL
in	NULL
samples	NULL
identified	NULL
as	NULL
Fy	NULL
(	NULL
b-	NULL
)	NULL
and	NULL
Fy	NULL
(	NULL
b	NULL
``	NULL
***	NULL
)	NULL
phenotypes	NULL
would	NULL
be	NULL
important	NULL
both	NULL
for	NULL
clinical	NULL
purposes	NULL
and	NULL
for	NULL
population	NULL
genetic	NULL
studies	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Cutbush	NULL
M	NULL
,	NULL
Mollison	NULL
PL	NULL
,	NULL
Parkin	NULL
DM	NULL
:	NULL
A	NULL
new	NULL
human	NULL
blood	NULL
group	NULL
.	NULL

Nature	NULL
165:188	NULL
,	NULL
1950	NULL
2	NULL
.	NULL

Sanger	NULL
R	NULL
,	NULL
Race	NULL
RR	NULL
,	NULL
Jack	NULL
J	NULL
:	NULL
The	NULL
Duffy	NULL
blood	NULL
groups	NULL
of	NULL
New	NULL
York	NULL
negroes	NULL
:	NULL
The	NULL
phenotype	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
1:370	NULL
,	NULL
1955	NULL
3	NULL
.	NULL

Reid	NULL
MEB	NULL
,	NULL
Lomas-Francis	NULL
C	NULL
:	NULL
The	NULL
Blood	NULL
Group	NULL
Antigen	NULL
Facts	NULL
Book	NULL
.	NULL

San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
Academic	NULL
,	NULL
1996	NULL
PARASOL	NULL
ET	NULL
AL	NULL
4	NULL
.	NULL

Donahue	NULL
RP	NULL
,	NULL
Bias	NULL
WB	NULL
,	NULL
Renwick	NULL
JH	NULL
,	NULL
McKusick	NULL
VA	NULL
:	NULL
Probable	NULL
assignment	NULL
of	NULL
the	NULL
Duffy	NULL
blood	NULL
group	NULL
locus	NULL
to	NULL
chromosome	NULL
1	NULL
in	NULL
man	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
61:949	NULL
,	NULL
1968	NULL
5	NULL
.	NULL

Mathew	NULL
S	NULL
,	NULL
Chaudhuri	NULL
A	NULL
,	NULL
Murty	NULL
VV	NULL
,	NULL
Pogo	NULL
AO	NULL
:	NULL
Confirmation	NULL
of	NULL
Duffy	NULL
blood	NULL
group	NULL
antigen	NULL
locus	NULL
(	NULL
FY	NULL
)	NULL
at	NULL
1q22	NULL
-	NULL
23	NULL
by	NULL
fluorescence	NULL
in	NULL
situ	NULL
hybridization	NULL
.	NULL

Cytogenet	NULL
Cell	NULL
Genet	NULL
67:68	NULL
,	NULL
1994	NULL
6	NULL
.	NULL

Chaudhuri	NULL
A	NULL
,	NULL
Polyakova	NULL
J	NULL
,	NULL
Zbrzezna	NULL
V	NULL
,	NULL
Williams	NULL
K	NULL
,	NULL
Gulati	NULL
S	NULL
,	NULL
Pogo	NULL
AO	NULL
:	NULL
Cloning	NULL
of	NULL
glycoprotein	NULL
D	NULL
cDNA	NULL
,	NULL
which	NULL
encodes	NULL
the	NULL
major	NULL
subunit	NULL
of	NULL
the	NULL
Duffy	NULL
blood	NULL
group	NULL
system	NULL
and	NULL
the	NULL
receptor	NULL
for	NULL
the	NULL
Plasmodium	NULL
vivax	NULL
malaria	NULL
parasite	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
90:10793	NULL
,	NULL
1993	NULL
7	NULL
.	NULL

Iwamoto	NULL
S	NULL
,	NULL
Li	NULL
J	NULL
,	NULL
Omi	NULL
T	NULL
,	NULL
Ikemoto	NULL
S	NULL
,	NULL
Kajii	NULL
E	NULL
:	NULL
Identification	NULL
of	NULL
a	NULL
novel	NULL
exon	NULL
and	NULL
spliced	NULL
form	NULL
of	NULL
Duffy	NULL
mRNA	NULL
that	NULL
is	NULL
the	NULL
predominant	NULL
transcript	NULL
in	NULL
both	NULL
erythroid	NULL
and	NULL
postcapillary	NULL
venule	NULL
endothelium	NULL
.	NULL

Blood	NULL
87:378	NULL
,	NULL
1996	NULL
8	NULL
.	NULL

Mallinson	NULL
G	NULL
,	NULL
Soo	NULL
KS	NULL
,	NULL
Schall	NULL
TJ	NULL
,	NULL
Pisacka	NULL
M	NULL
,	NULL
Anstee	NULL
DJ	NULL
:	NULL
Mutations	NULL
in	NULL
the	NULL
erythrocyte	NULL
chemokine	NULL
receptor	NULL
(	NULL
Duffy	NULL
)	NULL
gene	NULL
:	NULL
The	NULL
molecular	NULL
basis	NULL
of	NULL
the	NULL
Fy®/Fy®	NULL
antigens	NULL
and	NULL
identification	NULL
of	NULL
a	NULL
deletion	NULL
in	NULL
the	NULL
Duffy	NULL
gene	NULL
of	NULL
an	NULL
apparently	NULL
healthy	NULL
individual	NULL
with	NULL
the	NULL
Fy	NULL
(	NULL
a-b-	NULL
)	NULL
phenotype	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
90:823	NULL
,	NULL
1995	NULL
9	NULL
.	NULL

Iwamoto	NULL
S	NULL
,	NULL
Omi	NULL
T	NULL
,	NULL
Kajii	NULL
E	NULL
,	NULL
Ikemoto	NULL
S	NULL
:	NULL
Genomic	NULL
organization	NULL
of	NULL
the	NULL
glycophorin	NULL
D	NULL
gene	NULL
:	NULL
Duffy	NULL
blood	NULL
group	NULL
Fy®/Fy®	NULL
alloantigen	NULL
system	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
polymorphism	NULL
at	NULL
the	NULL
44-amino	NULL
acid	NULL
residue	NULL
.	NULL

Blood	NULL
85:622	NULL
,	NULL
1995	NULL
10	NULL
.	NULL

Chaudhuri	NULL
A	NULL
,	NULL
Polyakova	NULL
J	NULL
,	NULL
Zbrzezna	NULL
V	NULL
,	NULL
Pogo	NULL
AO	NULL
:	NULL
The	NULL
coding	NULL
sequence	NULL
of	NULL
Duffy	NULL
blood	NULL
group	NULL
gene	NULL
in	NULL
humans	NULL
and	NULL
simians	NULL
:	NULL
Restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
,	NULL
antibody	NULL
and	NULL
malarial	NULL
parasite	NULL
specifici-ties	NULL
,	NULL
and	NULL
expression	NULL
in	NULL
nonerythroid	NULL
tissues	NULL
in	NULL
Duffy-negative	NULL
individuals	NULL
.	NULL

Blood	NULL
85:615	NULL
,	NULL
1995	NULL
11	NULL
.	NULL

Tournamille	NULL
C	NULL
,	NULL
Colin	NULL
Y	NULL
,	NULL
Cartron	NULL
JP	NULL
,	NULL
Le	NULL
Van	NULL
Kim	NULL
C	NULL
:	NULL
Disruption	NULL
of	NULL
a	NULL
GATA	NULL
motif	NULL
in	NULL
the	NULL
Duffy	NULL
gene	NULL
promoter	NULL
abolishes	NULL
erythroid	NULL
gene	NULL
expression	NULL
in	NULL
Duffy-negative	NULL
individuals	NULL
.	NULL

Nature	NULL
Genet	NULL
10:224	NULL
,	NULL
1995	NULL
12	NULL
.	NULL

Hadley	NULL
TJ	NULL
,	NULL
Peiper	NULL
SC	NULL
:	NULL
From	NULL
malaria	NULL
to	NULL
chemokine	NULL
receptor	NULL
:	NULL
The	NULL
emerging	NULL
physiologic	NULL
role	NULL
of	NULL
the	NULL
Duffy	NULL
blood	NULL
group	NULL
antigen	NULL
.	NULL

Blood	NULL
89:3077	NULL
,	NULL
1997	NULL
13	NULL
.	NULL

Neote	NULL
K	NULL
,	NULL
Mak	NULL
JY	NULL
,	NULL
Kolakowski	NULL
LF	NULL
Jr	NULL
,	NULL
Schall	NULL
TJ	NULL
:	NULL
Functional	NULL
and	NULL
biochemical	NULL
analysis	NULL
of	NULL
the	NULL
cloned	NULL
Duffy	NULL
antigen	NULL
:	NULL
Identity	NULL
with	NULL
the	NULL
red	NULL
blood	NULL
cell	NULL
chemokine	NULL
receptor	NULL
.	NULL

Blood	NULL
84:44	NULL
,	NULL
1994	NULL
14	NULL
.	NULL

Horuk	NULL
R	NULL
,	NULL
Martin	NULL
A	NULL
,	NULL
Hesselgesser	NULL
J	NULL
,	NULL
Hadley	NULL
T	NULL
,	NULL
Lu	NULL
ZH	NULL
,	NULL
Wang	NULL
ZX	NULL
,	NULL
Peiper	NULL
SC	NULL
:	NULL
The	NULL
Duffy	NULL
antigen	NULL
receptor	NULL
for	NULL
chemokines	NULL
:	NULL
Structural	NULL
analysis	NULL
and	NULL
expression	NULL
in	NULL
the	NULL
brain	NULL
.	NULL

J	NULL
Leukoc	NULL
Biol	NULL
59:29	NULL
,	NULL
1996	NULL
15	NULL
.	NULL

Murphy	NULL
MT	NULL
,	NULL
Templeton	NULL
LJ	NULL
,	NULL
Fleming	NULL
J	NULL
,	NULL
Ferguson	NULL
M	NULL
,	NULL
Peterkin	NULL
M	NULL
,	NULL
Fraser	NULL
RH	NULL
:	NULL
Comparison	NULL
of	NULL
Fy	NULL
(	NULL
b	NULL
)	NULL
status	NULL
as	NULL
determined	NULL
serologically	NULL
and	NULL
genetically	NULL
.	NULL

Transf	NULL
Med	NULL
7:135	NULL
,	NULL
1997	NULL
16	NULL
.	NULL

Saha	NULL
N	NULL
,	NULL
Tay	NULL
JSH	NULL
,	NULL
Tsoi	NULL
WF	NULL
,	NULL
Kua	NULL
EH	NULL
:	NULL
Association	NULL
of	NULL
Duffy	NULL
blood	NULL
group	NULL
with	NULL
schizophrenia	NULL
in	NULL
Chinese	NULL
.	NULL

Genetic	NULL
Epidemiol	NULL
7:303	NULL
,	NULL
1990	NULL
17	NULL
.	NULL

Kosower	NULL
NS	NULL
,	NULL
Gerad	NULL
L	NULL
,	NULL
Goldstein	NULL
M	NULL
,	NULL
Parasol	NULL
N	NULL
,	NULL
Zipser	NULL
Y	NULL
,	NULL
Ragolsky	NULL
M	NULL
,	NULL
Rozencwaig	NULL
S	NULL
,	NULL
Elkabetz	NULL
E	NULL
,	NULL
Abramovitch	NULL
Y	NULL
,	NULL
Lerer	NULL
B	NULL
,	NULL
Weizman	NULL
A	NULL
:	NULL
Constitutive	NULL
heterochromatin	NULL
of	NULL
chromosome	NULL
1	NULL
and	NULL
Duffy	NULL
blood	NULL
group	NULL
alleles	NULL
in	NULL
schizophrenia	NULL
.	NULL

Am	NULL
J	NULL
Med	NULL
Genet	NULL
60:133	NULL
,	NULL
1995	NULL
18	NULL
.	NULL

Miller	NULL
SA	NULL
,	NULL
Dykes	NULL
DD	NULL
,	NULL
Polesky	NULL
HF	NULL
:	NULL
A	NULL
simple	NULL
salting	NULL
out	NULL
procedure	NULL
for	NULL
extracting	NULL
DNA	NULL
from	NULL
human	NULL
nucleated	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
16:1215	NULL
,	NULL
1988	NULL
19	NULL
.	NULL

Race	NULL
RR	NULL
,	NULL
Sanger	NULL
R	NULL
:	NULL
Blood	NULL
Groups	NULL
in	NULL
Man	NULL
.	NULL

Oxford	NULL
,	NULL
UK	NULL
,	NULL
Blackwell	NULL
Scientific	NULL
,	NULL
1975	NULL
20	NULL
.	NULL

Sandler	NULL
SG	NULL
,	NULL
Kravitz	NULL
C	NULL
,	NULL
Sharon	NULL
R	NULL
,	NULL
Hermoni	NULL
D	NULL
,	NULL
Ezekiel	NULL
E	NULL
,	NULL
Cohen	NULL
T	NULL
:	NULL
The	NULL
Duffy	NULL
blood	NULL
group	NULL
system	NULL
in	NULL
Israeli	NULL
Jews	NULL
and	NULL
Arabs	NULL
.	NULL

Vox	NULL
Sang	NULL
37:41	NULL
,	NULL
1979	NULL
21	NULL
.	NULL

Silva	NULL
RC	NULL
,	NULL
Castilho	NULL
LM	NULL
,	NULL
Milare	NULL
MS	NULL
,	NULL
Pellegrino	NULL
J	NULL
Jr	NULL
:	NULL
Distribution	NULL
of	NULL
the	NULL
Kell	NULL
,	NULL
Duffy	NULL
and	NULL
Kidd	NULL
blood	NULL
groups	NULL
in	NULL
blood	NULL
donors	NULL
.	NULL

Rev	NULL
Paul	NULL
Med	NULL
110	NULL
(	NULL
8	NULL
)	NULL
:33	NULL
,	NULL
1992	NULL
(	NULL
abstr	NULL
,	NULL
suppl	NULL
)	NULL
22	NULL
.	NULL

Tournamille	NULL
C	NULL
,	NULL
Le	NULL
Van	NULL
Kim	NULL
C	NULL
,	NULL
Gane	NULL
P	NULL
,	NULL
Blanchard	NULL
D	NULL
,	NULL
Proudfoot	NULL
AE	NULL
,	NULL
Cartron	NULL
JP	NULL
,	NULL
Colin	NULL
Y	NULL
:	NULL
Close	NULL
association	NULL
of	NULL
the	NULL
first	NULL
and	NULL
fourth	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

NOVEL	NULL
MUTATION	NULL
IN	NULL
DARC	NULL
ASSOCIATED	NULL
WITH	NULL
ALTERED	NULL
PHENOTYPE	NULL
extracellular	NULL
domains	NULL
of	NULL
the	NULL
Duffy	NULL
antigen/receptor	NULL
for	NULL
chemokines	NULL
by	NULL
a	NULL
disulfide	NULL
bond	NULL
is	NULL
required	NULL
for	NULL
ligand	NULL
binding	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:16274	NULL
,	NULL
1997	NULL
23	NULL
.	NULL

Szabo	NULL
MC	NULL
,	NULL
Soo	NULL
KS	NULL
,	NULL
Zlotnik	NULL
A	NULL
,	NULL
Schall	NULL
TJ	NULL
:	NULL
;	NULL
Chemokine	NULL
class	NULL
differences	NULL
in	NULL
binding	NULL
to	NULL
the	NULL
Duffy	NULL
antigen-erythrocyte	NULL
chemokine	NULL
receptor	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:25348	NULL
,	NULL
1995	NULL
24	NULL
.	NULL

Sosler	NULL
SD	NULL
,	NULL
Perkins	NULL
JT	NULL
,	NULL
Fong	NULL
K	NULL
,	NULL
Saporito	NULL
C	NULL
:	NULL
The	NULL
prevalence	NULL
of	NULL
immunization	NULL
to	NULL
Duffy	NULL
antigens	NULL
in	NULL
a	NULL
population	NULL
of	NULL
known	NULL
racial	NULL
distribution	NULL
.	NULL

Transfusion	NULL
29:505	NULL
,	NULL
1989	NULL
25	NULL
.	NULL

Sandler	NULL
SG	NULL
,	NULL
Mallory	NULL
D	NULL
,	NULL
Wolfe	NULL
JS	NULL
,	NULL
Byme	NULL
P	NULL
,	NULL
Lucas	NULL
DM	NULL
:	NULL
Screening	NULL
with	NULL
monoclonal	NULL
anti-Fy3	NULL
to	NULL
provide	NULL
blood	NULL
for	NULL
phenotype	NULL
2243	NULL
matched	NULL
transfusions	NULL
for	NULL
patients	NULL
with	NULL
sickle	NULL
cell	NULL
disease	NULL
.	NULL

Transfusion	NULL
37:393	NULL
,	NULL
1997	NULL
26	NULL
.	NULL

Mullighan	NULL
CG	NULL
,	NULL
Marshall	NULL
SE	NULL
,	NULL
Fanning	NULL
GC	NULL
,	NULL
Briggs	NULL
DC	NULL
,	NULL
Welsh	NULL
KT	NULL
:	NULL
Rapid	NULL
haplotyping	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
Duffy	NULL
gene	NULL
using	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
and	NULL
sequence-specific	NULL
primers	NULL
.	NULL

Tissue	NULL
Antigens	NULL
51:195	NULL
,	NULL
1998	NULL
27	NULL
.	NULL

Olsson	NULL
ML	NULL
,	NULL
Hansson	NULL
C	NULL
,	NULL
Avent	NULL
ND	NULL
,	NULL
Akesson	NULL
IB	NULL
,	NULL
Green	NULL
CA	NULL
,	NULL
Daniels	NULL
GL	NULL
:	NULL
A	NULL
clinically	NULL
applicable	NULL
method	NULL
for	NULL
determining	NULL
the	NULL
three	NULL
major	NULL
alleles	NULL
at	NULL
the	NULL
Duffy	NULL
(	NULL
FY	NULL
)	NULL
blood	NULL
group	NULL
locus	NULL
using	NULL
polymerase	NULL
chain	NULL
reaction	NULL
with	NULL
allele-specific	NULL
primers	NULL
.	NULL

Transfusion	NULL
38:168	NULL
,	NULL
1998	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
blO	NULL
0d	NULL
1998	NULL
92	NULL
:	NULL
2237-2243	NULL
A	NULL
Novel	NULL
Mutation	NULL
in	NULL
the	NULL
Coding	NULL
Sequence	NULL
of	NULL
the	NULL
FY*B	NULL
Allele	NULL
of	NULL
the	NULL
Duffy	NULL
Chemokine	NULL
Receptor	NULL
Gene	NULL
Is	NULL
Associated	NULL
With	NULL
an	NULL
Altered	NULL
Erythrocyte	NULL
Phenotype	NULL
A	NULL
_	NULL
48	NULL
o	NULL
6	NULL
'	NULL
t	NULL
\se	NULL
@	NULL
.	NULL

/	NULL
{	NULL
®	NULL
Niva	NULL
Parasol	NULL
,	NULL
Marion	NULL
Reid	NULL
,	NULL
Maria	NULL
Rios	NULL
,	NULL
Lilian	NULL
Castilho	NULL
,	NULL
lana	NULL
Harari	NULL
and	NULL
Nechama	NULL
S.	NULL
Kosower	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/92/7/2237.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

